4.08
4.67%
-0.20
Aquestive Therapeutics Inc stock is currently priced at $4.08, with a 24-hour trading volume of 896.19K.
It has seen a -4.67% decreased in the last 24 hours and a -6.85% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.34 pivot point. If it approaches the $3.92 support level, significant changes may occur.
Previous Close:
$4.28
Open:
$4.25
24h Volume:
896.19K
Market Cap:
$365.72M
Revenue:
$50.58M
Net Income/Loss:
$-7.87M
P/E Ratio:
-9.0667
EPS:
-0.45
Net Cash Flow:
$-7.38M
1W Performance:
+4.08%
1M Performance:
-6.85%
6M Performance:
+185.31%
1Y Performance:
+200.00%
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908 941 1900
Address
30 Technology Drive, Warren, NJ
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Apr-22-19 | Initiated | H.C. Wainwright | Buy |
Jan-03-19 | Initiated | Lake Street | Buy |
Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
GlobeNewswire Inc.
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Benzinga
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Zacks Investment Research
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
Zacks Investment Research
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Aquestive Therapeutics Inc (AQST) Revenue 2024
AQST reported a revenue (TTM) of $50.58 million for the quarter ending December 31, 2023, a +6.09% rise year-over-year.
Aquestive Therapeutics Inc (AQST) Net Income 2024
AQST net income (TTM) was -$7.87 million for the quarter ending December 31, 2023, a +85.54% increase year-over-year.
Aquestive Therapeutics Inc (AQST) Cash Flow 2024
AQST recorded a free cash flow (TTM) of -$7.38 million for the quarter ending December 31, 2023, a +40.25% increase year-over-year.
Aquestive Therapeutics Inc (AQST) Earnings per Share 2024
AQST earnings per share (TTM) was -$0.1541 for the quarter ending December 31, 2023, a +86.48% growth year-over-year.
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Cap:
|
Volume (24h):